The Bombay Burmah Trading Corporation (501425) Q4 99/00 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 99/00 earnings summary
22 Oct, 2026Executive summary
Financial year extended to 18 months, 1 Apr 1999–30 Sep 2000, to absorb the impact of prolonged labour disruption at Singampatti tea estates.
Results swung to a loss amid reduced plantation output, higher labour costs, pressure on tea prices and uneconomic particle-board operations.
Financial highlights
Gross income was Rs 19,370.33 lakhs; loss before tax Rs 1,611.11 lakhs and loss after tax Rs 1,638.32 lakhs, versus prior-year 12-month profit after tax of Rs 7.86 lakhs; periods are not comparable.
Gross loss before depreciation was Rs 871.48 lakhs, compared with gross profit before depreciation of Rs 866.46 lakhs in the prior 12-month year.
Directors recommended a 10% dividend, Re 1 per share, funded from reserves.
Outlook and guidance
Plantation strategy under review; options to grow organic tea include strategic alliances, licences and leases.
Formica cost-reduction and operating-improvement measures began showing positive results from June 2000; Afcoset balances outlook described as favourable.
Restructuring options for Central India Board Products were under examination after operations at Itarsi were suspended.
Latest events from The Bombay Burmah Trading Corporation
- Higher profit, softer sales and negative operating cash flow defined FY 1996-97.501425
Q4 96/97 - Profit rose on stronger plantation realisations; new manufacturing lines launched.501425
Q4 97/98 - Labor disruption and particle-board losses drove a steep FY99 profit decline.501425
Q4 98/99 - Commodity-price pressure and estate disruptions drove another loss; the dividend was skipped.501425
Q4 01/02 - Profit returned as operational gains offset weak tea and coffee markets.501425
Q4 02/03 - Profit rebounded as lower financing costs and industrial gains offset plantation pressures.501425
Q4 03/04 - Higher profits and associate earnings met drought, cost and currency pressures.501425
Q4 04/05 - FY06 profit rose amid cost pressure, with expansion and healthcare poised to drive growth.501425
Q4 05/06 - Standalone earnings improved; acquisitions and new capacity set up growth, with VRS costs deferred to FY08.501425
Q4 06/07